Clinical differences at baseline between the STAT 3 SH2 domain mutated and nonmutated LGL leukemia patients
| Variable . | STAT 3 SH2 domain mutated patients (48) . | STAT 3 SH2 domain nonmutated (122) . | P . |
|---|---|---|---|
| Age | .96 | ||
| Median, y | 63 | 64 | |
| Range, y | 35-80 | 20-90 | |
| Sex, no. (%) | .06 | ||
| Male | 58 (28) | 52 (66) | |
| Female | 42 (20) | 48 (54) | |
| Symptoms at diagnosis, no. (%) | 75 (36) | 45 (54) | < .001 |
| Neutropenia, no. (%)* | 70 (34) | 59 (71) | .14 |
| Lymphocytosis, no. (%)† | 56 (27) | 52 (65) | .7 |
| Anemia, no. (%)‡ | 50 (24) | 34 (28) | .06 |
| Thrombocytopenia, no. (%)§ | 13 (6) | 15 (18) | .7 |
| LGL count in PB, × 109/L | 3.9 | 3.3 | .45 |
| Median | 0.4-20 | 0.5-9 | |
| Splenomegaly, no. (%) | 33 (16) | 26 (32) | .5 |
| Presence of MGUS, no. (%) | 14 (8) | 20 (28) | .3 |
| Associated autoimmune disease, no. (%) | 22 | 24 | .052 |
| RA, no. (%) | 18 (9) | 7 (8) | .039 |
| AIHA, no. (%) | 14 (7) | 4 (5) | |
| Associated BM disorder | |||
| MDS, no. (%) | 8 (4) | 5 (6) | .437 |
| PRCA, no. (%) | 0 | 6 (8) | .027 |
| Presence of B-cell malignancy, no. (%) | 4 (2) | 10 (13) | .162 |
| Treatment lines | .03 | ||
| Median | 2.4 | 1.2 | |
| Lineage, no. (%) | .6 | ||
| T-cell | 28 (33) | 72 (89) | |
| NK-cell | 30 (15) | 70 (35) |
| Variable . | STAT 3 SH2 domain mutated patients (48) . | STAT 3 SH2 domain nonmutated (122) . | P . |
|---|---|---|---|
| Age | .96 | ||
| Median, y | 63 | 64 | |
| Range, y | 35-80 | 20-90 | |
| Sex, no. (%) | .06 | ||
| Male | 58 (28) | 52 (66) | |
| Female | 42 (20) | 48 (54) | |
| Symptoms at diagnosis, no. (%) | 75 (36) | 45 (54) | < .001 |
| Neutropenia, no. (%)* | 70 (34) | 59 (71) | .14 |
| Lymphocytosis, no. (%)† | 56 (27) | 52 (65) | .7 |
| Anemia, no. (%)‡ | 50 (24) | 34 (28) | .06 |
| Thrombocytopenia, no. (%)§ | 13 (6) | 15 (18) | .7 |
| LGL count in PB, × 109/L | 3.9 | 3.3 | .45 |
| Median | 0.4-20 | 0.5-9 | |
| Splenomegaly, no. (%) | 33 (16) | 26 (32) | .5 |
| Presence of MGUS, no. (%) | 14 (8) | 20 (28) | .3 |
| Associated autoimmune disease, no. (%) | 22 | 24 | .052 |
| RA, no. (%) | 18 (9) | 7 (8) | .039 |
| AIHA, no. (%) | 14 (7) | 4 (5) | |
| Associated BM disorder | |||
| MDS, no. (%) | 8 (4) | 5 (6) | .437 |
| PRCA, no. (%) | 0 | 6 (8) | .027 |
| Presence of B-cell malignancy, no. (%) | 4 (2) | 10 (13) | .162 |
| Treatment lines | .03 | ||
| Median | 2.4 | 1.2 | |
| Lineage, no. (%) | .6 | ||
| T-cell | 28 (33) | 72 (89) | |
| NK-cell | 30 (15) | 70 (35) |
PB indicates peripheral blood; MGUS, monoclonal gammopathy of undetermined significance; MDS, myelodysplastic syndrome; STAT3, signal transducer and activator of transcription 3; and SH2, Src homology 2 domain.
Absolute neutrophil count ≤ 1.5 × 109/L.
Absolute lymphocyte count ≥ 4 × 109/L.
Hemoglobin ≤ 10 g/dL.
Platelet count ≤ 100 × 109/L.